Geographic factors associated with poorer outcomes in patients diagnosed with covid-19 in primary health care by Magallón-Botaya, R. et al.




Geographic Factors Associated with Poorer Outcomes in
Patients Diagnosed with COVID-19 in Primary Health Care
Rosa Magallón-Botaya 1,2,3 , Bárbara Oliván-Blázquez 1,3,4,* , Karen Lizzette Ramírez-Cervantes 5,6,7 ,
Fátima Méndez-López-de-la-Manzanara 1, Isabel Aguilar-Palacio 1,8,9 , Marc Casajuana-Closas 3,10








M.; Andrés-Esteban, E. Geographic
Factors Associated with Poorer
Outcomes in Patients Diagnosed with
COVID-19 in Primary Health Care.
Int. J. Environ. Res. Public Health 2021,
18, 3842. https://doi.org/10.3390/
ijerph18073842
Academic Editors: Manoj Sivan, Ng
Yee Sien and Sofia Straudi
Received: 2 February 2021
Accepted: 2 April 2021
Published: 6 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 GAIAP Research Group, Institute for Health Research Aragon (IIS Aragon), 50009 Zaragoza, Spain;
rosamaga@unizar.es (R.M.-B.); fatima.lopezmendez@hotmail.com (F.M.-L.-d.-l.-M.);
iaguilar@unizar.es (I.A.-P.)
2 Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, 50009 Zaragoza, Spain
3 Research Network on Preventive Activities and Health Promotion (RedIAPP), 08007 Barcelona, Spain;
mcasajuana@idiapjgol.info
4 Department of Psychology and Sociology, University of Zaragoza, 50009 Zaragoza, Spain
5 Department of Applied Economics, Rey Juan Carlos University, 28300 Madrid, Spain;
karenlizzetteramirez@gmail.com (K.L.R.-C.); e.andres@live.com (E.A.-E.)
6 Bleeding Patient Research Group, Idi-Paz Research Institute, 28029 Madrid, Spain
7 Prevention Department, Spanish Association against Cancer, 28040 Madrid, Spain
8 Department of Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain
9 GRISSA Research Group, 50009 Zaragoza, Spain
10 Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol),
08007 Barcelona, Spain
* Correspondence: barbaraolivan@gmail.com
Abstract: Background: The prognosis of older age COVID-19 patients with comorbidities is associated
with a more severe course and higher fatality rates but no analysis has yet included factors related to
the geographical area/municipality in which the affected patients live, so the objective of this study
was to analyse the prognosis of patients with COVID-19 in terms of sex, age, comorbidities, and
geographic variables. Methods: A retrospective cohort of 6286 patients diagnosed with COVID-19
was analysed, considering demographic data, previous comorbidities and geographic variables. The
main study variables were hospital admission, intensive care unit (ICU) admission and death due
to worsening symptoms; and the secondary variables were sex, age, comorbidities and geographic
variables (size of the area of residence, distance to the hospital and the driving time to the hospital).
A comparison analysis and a multivariate Cox model were performed. Results: The multivariate
Cox model showed that women had a better prognosis in any type of analysed prognosis. Most of
the comorbidities studied were related to a poorer prognosis except for dementia, which is related
to lower admissions and higher mortality. Suburban areas were associated with greater mortality
and with less hospital or ICU admission. Distance to the hospital was also associated with hospital
admission. Conclusions: Factors such as type of municipality and distance to hospital act as social
health determinants. This fact must be taken account in order to stablish specifics prevention
measures and treatment protocols.
Keywords: COVID-19; primary health care; geographic factors; outcomes
1. Introduction
As of 5 January 2021, more than 83 million cases of the novel coronavirus disease 2019
(COVID-19) have been detected worldwide, and more than 1.8 million people have died
from the disease [1]. Spain has become one of the countries most affected by the disease,
and one of the countries with the highest COVID-19 testing rates [2–4].
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The response of National Health Service (NHS), especially that of Primary Health
Care (PHC), has been crucial for containing COVID-19 [5]. Spain has included maintaining
essential services by cancelling or postponing non-urgent activities and elective surgeries.
Moreover, barriers to accessing usual care were mitigated by enhancing phone helplines,
online assistance and emergency call centres [6]. Furthermore, the PHC services had to
be reorganised according to their rural, urban or suburban characteristics, and home care
and telemedicine were reinforced [3]. The first medical contact for COVID-19 cases is
commonly through a PHC team, which determines the severity of symptoms, manages the
follow-up of mild cases and organises the hospital referrals for moderate-severe cases [3].
However, the urban-rural gap could have affected the way in which the current health
crisis was confronted [7]. In 2019, for instance, people over the age of 65 years represented
28.5% of the population of rural communities (≤2000 inhabitants) compared with 19.7%
and 18.3% of suburban and urban communities, respectively [8]. In addition, 42% of older
adults from rural areas considered that distance posed a major difficulty in accessing a
PHC centre, which, along with a greater dependency for performing activities of daily
living for this group and a lack of public transportation, could have caused an uneven
impact of COVID-19 [9].
The Spanish NHS is decentralised; each of the 17 autonomous communities is respon-
sible for the territorial administration of primary and hospital-based health services [10].
There are 13.163 PHC centres in Spain [11]; however, due to asymmetric population density,
the centres are not uniformly distributed, with basic health areas in the smallest health care
units each covering 2000–10,000 inhabitants. As observed in other territories [12,13], the
current statistics show that the incidence of COVID-19 has been unequal across Spain [14].
For instance, recent Catalan studies have shown that the spread of the disease was slower
in rural territories than in urban areas, being 6.5% higher in basic health areas with twice
the population density [15]. However, the introduction of an infected individual into
small but dense groups, can negatively impact the spread of the disease, as observed in
several rural communities where a high incidence rate was related to the presence of a
COVID-19-positive individual at highly attended funerals.
In countries such as India, 25% of COVID-19-related deaths have occurred in rural
and suburban districts [12]. In the United States, the COVID-19 incidence and mortality
rates of small and nonmetropolitan cities have been comparable to those of large cities [13].
An increasing number of articles have been addressing the prognosis of patients with
COVID-19, showing that older age and comorbidities, were associated with a more severe
course and higher fatality rates among individuals hospitalised for COVID-19 [16–18]. To
our knowledge, no analysis has related factors related to the geographical area/municipality
in which the affected patients live and their geographic accessibility to a referral hospital.
In countries such as Spain, specifically, the autonomous community of Aragon, having
large rural areas and low population densities, the effects of spatial disparities on disease
outcomes remain unknown. Aragón has an area of 47,719 km2 and a population density of
28.20 inhabitants per km2, with a higher proportion of older adults than younger ones. The
older adults are more concentrated in rural areas, while the cities have younger populations.
Zaragoza, the capital, contains half of the community’s population, with only 13 munic-
ipalities exceeding 10,000 inhabitants. Rural nuclei (with fewer than 2000 inhabitants)
represent 86% of the municipalities, where only 16.8% of the population lives. The popula-
tion pyramid graph for Aragon [14] shows a contracting structure. The main age group
is 30–49 years (active population), which has been augmented by a significant increase
in the immigrant population since 2000. However, population older than 65 years has
grown significantly since the beginning of the century, a common feature in all developed
regions. The origins of this situation include a substantial reduction in fertility rates, and
an increase in life expectancy at birth. This region’s geographical and demographic charac-
teristics make it comparable to many other regions of inland Spain and other European and
American countries with high levels of ageing, geographical dispersion and depopulation.
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The pyramid shows low crude birth rates due to the small number of initial cohorts (aged
0–4 years) and the low crude death rates.
The objective of this study was therefore to analyse the prognosis (hospital admission,
intensive care unit (ICU) admission and death) of patients with COVID-19 in terms of sex,
age, comorbidities, and geographics variables.
2. Materials and Methods
We conducted a retrospective cohort study that considered demographic data, previ-
ous comorbidities and geographics variables of 6286 patients diagnosed with COVID-19 in
Aragon (Spain) from the beginning of the current pandemic to 30 June 2020.
The inclusion criteria were: 18 years of age and older and having a diagnostic code
of “coronavirus infection” with a positive polymerase chain reaction (PCR) diagnostic
test result. Due to the universal nature of the NHS, the data obtained are considered
representative of practically 100% of the population who met the criteria for inclusion.
The primary study variables were: hospital admission, ICU admission and death due
to COVID-19. the secondary variables were the following:
(1) Sociodemographic data: sex and age.
(2) Previous medical history: previous cardiovascular diseases (CVD): chronic heart
disease, heart failure, cerebrovascular disease, hypertension, dyslipidaemia, pre-
vious chronic respiratory diseases, chronic renal diseases, chronic liver diseases,
chronic neurological disorders, chronic haematological diseases (leukaemia, lym-
phoma, myeloma), cancer/neoplasia, HIV and other immunodeficiencies, obesity,
diabetes, dermatological diseases, rheumatological diseases, mental disorders and
dementia. The diseases were classified according to the International Classification of
Diseases 11th Revision [19].
(3) Geographic variables: The size of the area of residence (rural areas were defied as
municipalities with a population of fewer than 2000 inhabitants, suburban areas were
defined as towns with 2000 to 10,000 inhabitants, and urban areas were defined as
having more than 10,000 inhabitants), municipalities with nursing home care (yes/no),
distance (Km) from the residence to the hospital and the driving time (minutes) from
the residence to the hospital.
For statistical analysis, we extracted all data on the demographics, clinical treatments,
and outcomes from the available Electronic Medical Records. We described the continuous
variables using robust statistics, such as median and interquartile range (IQR) due to the
non-normality of the variables as confirmed by the Shapiro Wilk test. On the other hand,
descriptive analyses of the categorical data were based on their frequency distribution.
For the comparison of continuous data between groups, non-normality distribution was
considered and in this specific case, we were unable to use the usual statistics test. Therefore,
we used the Mann–Whitney nonparametric U test [20]. To compare categorical variables
between the good/poor (hospital admission, ICU admission and death) prognosis groups,
the Chi-squared test was used.
We performed the survival estimates with the Kaplan–Meier method [21], compar-
ing the survival curves according to the prognosis groups; the Wilcoxon test was used
instead classical log-rank because survival curves did not reach the median survival [22].
Multivariate analysis was performed by a Cox regression model using a forward stepwise
procedure, introducing as independent variables the poorest prognosis factor. The results
of the multivariate model are presented as a hazard ratio (HR; 95% CI). This regression
model is common when modelling time to event (considering event: time to hospitalize,
ICU admission or death).
The statistical analysis was performed using STATA/SE V16.0 (company, city, state
abbrev if USA, country), and p-values < 0.05 were considered statistically significant.
All procedures contributing to this study complied with the ethical standards of the
Helsinki Declaration of 1975 (revised in 2008). The study protocol was approved by the
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Clinical Research Ethics Committee of Aragón (PI20/262). Clinical data were used in a
nonidentifiable format.
3. Results
Of the 6286 patients studied, 2738 (43.56%) were men, 4440 (71.72%) lived in urban
areas, and the median age was 61 years (IQR 61–82). Table 1 lists the demographic char-
acteristics and the prevalence of previous diseases. The patients were significantly older
in the poorest prognosis groups, regardless of whether the patients were in the hospital
admission, ICU admission or death groups. The female sex was associated with a better
prognosis (Table 1). With a considerably lower ICU admission rate, than among men (28.7%
vs. 62.2%) and a lower final mortality rate (48.5% vs. 57.9%) and hospital admission rate
(47.6% vs. 62.2%) than the men.
There was a statistically significant correlation with the size of the patients’ area of
residence. Patients living in urban areas had poorer prognoses in terms of hospital and
ICU admissions. However, this tendency did not occur with respect to mortality, given
that 65.39% of the patients who died lived in urban areas compared with 72.77% of those
who survived (p < 0.01). The prevalence rate of patients with COVID-19 in each of the 3
analysed areas shows a high prevalence in the suburban zone, with 48 cases per 10,000
inhabitants in the urban zones, 55 cases per 10,000 inhabitants in the suburban zones, and
35 cases per 10,000 inhabitants in the rural zones. The analysed distance to the hospitals
through the median distance and time of arrival to the hospital (Table 1) also proved to be
significant.
Table 1. Sociodemographic data and previous comorbidities according to different prognoses.
Sociodemographic Data
Hospital Admission ICU Admission Death
No Yes p No Yes p No Yes p
n (%) 3797 (60.40%) 2489 (39.60%) 6034 (95.99%) 252 (4.01%) 5313 (84.52%) 973 (15.48%)
Age * 52 (39–72) 75 (61–86) <0.001 45 (60–83) 67 (59–74) 0.002 56 (43–74) 86 (79–92) <0.001
Sex
<0.001 <0.001 <0.001Male 1434 (37.77%) 1304 (52.39%) 2557 (42.38%) 181 (71.83%) 2237 (42.10%) 501 (51.49%)
Female 2363 (62.23%) 1185 (47.61%) 3477 (57.62%) 71 (28.71%) 3076 (57.90%) 472 (48.51%)
Municipality
classification
0.002 0.009 <0.001Rural 430 (11.52%) 302 (12.24%) 696 (11.69%) 36 (14.63%) 622 (11.88%) 110 (11.40%)
Suburban 559 (17.93%) 358 (14.51%) 1003 (16.85%) 24 (9.76%) 803 (15.34%) 224 (23.21%)
Urban 2633 (70.55%) 1807 (73.25%) 4254 (71.46%) 186 (75.61%) 3809 (72.77%) 631 (65.39%)
Municipality—hospital




0 (0–23) 0 (0–19) <0.001 0 (0–23) 0 (0–17) 0.127 0 (0–22) 0 (0–25) 0.015
* Continuous variables. Median and IQR are shown. For the remainder of the (categorical) variables, the number of subjects and percentage
is shown.
In terms of previous comorbidity (Table 2), the poorer prognoses were associated with
a higher prevalence of any of the diseases studied, except for HIV and other immunodefi-
ciency diseases.
In the case of ICU admissions, neither CKD (p = 0.891) nor chronic neurological
disease (p = 0.143) were statistically significant. Also, other diagnoses such as neoplasia,
HIV, malnutrition, dermatological or rheumatological disorders were not related to ICU
admissions. In the case of mortality, chronic liver disease was the only comorbidity having
a similar distribution among patients who died and those who did not (p = 0.835). HIV
was not significant in any case, except for hospital admission (p-value = 0.048), although
the rate of this diagnosis was very low. Obesity, on the other hand, doubles its rate in
hospitalized patients (hospital or ICU admission) but was not significant in mortality.
Figures 1–3 show the patients’ characteristics according to prognosis, with the survival
curves according to the size of the residents’ area and the p-value based on the log-rank
test. In the Kaplan–Meier curves, we observed that the poorest prognosis was related to
suburban areas where fewer people were admitted to hospital than in the other municipali-
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ties; nevertheless, the COVID-19-related mortality in these areas was higher than in the
other areas studied.
Table 2. Previous comorbidities.
Hospital Admission ICU Admission Death




1013 (26.68%) 1168 (46.93%) <0.001 1013 (26.68%) 1168 (46.93%) <0.001 1013 (26.68%) 1168 (46.93%) <0.001
Hypertension 961 (25.31%) 1290 (51.83%) <0.001 2124 (35.20%) 127 (50.40%) <0.001 1612 (30.34%) 639 (65.57%) <0.001
Dyslipidaemia 897 (23.62%) 1060 (42.83%) <0.001 1828 (30.29%) 135 (53.57%) <0.001 1551 (29.19%) 412 (42.34%) <0.001
Previous
respiratory disease 306 (8.06%) 348 (13.98%) <0.001 306 (8.06%) 348 (13.98%) <0.001 306 (8.06%) 348 (13.98%) <0.001
Chronic kidney
disease 212 (5.58%) 352 (14.14%) <0.001 542 (8.98%) 22 (8.73%) 0.891 348 (6.55%) 216 (22.20%) <0.001
Chronic liver















1205 (31.74%) 1185 (47.61%) <0.001 2263 (37.50%) 127 (50.40%) <0.001 1828 (34.41%) 562 (57.76%) <0.001
Neoplasia 258 (6.79%) 369 (14.83%) <0.001 596 (9.88%) 31 (12.30%) 0.208 436 (8.21%) 191 (19.63%) <0.001
HIV and other im-
munodeficiencies 25 (0.66%) 28 (1.12%) 0.048 50 (0.83%) 3 (1.19%) 0.538 40 (0.75%) 13 (1.34%) 0.067
Obesity 321 (8.45%) 366 (14.70%) <0.001 629 (10.42%) 58 (23.02%) <0.001 574 (10.80%) 113 (11.61%) 0.457
Malnutrition 549 (14.46%) 522 (20.97%) <0.001 1022 (16.94%) 49 (19.44%) 0.300 819 (15.42%) 252 (25.90%) <0.001
Diabetes 319 (8.40%) 496 (19.93%) <0.001 758 (12.56%) 57 (22.62%) <0.001 569 (10.71%) 246 (25.28%) <0.001
Mental illness 784 (20.65%) 694 (27.88%) <0.001 1433 (23.75%) 45 (17.86%) 0.031 1163 (21.89%) 315 (32.37%) <0.001
Dementia 311 (8.19%) 365 (14.66%) <0.001 673 (11.15%) 3 (1.19%) <0.001 381 (7.17%) 295 (30.32%) <0.001
Dermatological
disease 1355 (35.69%) 1063 (42.71%) <0.001 2317 (38.40%) 101 (40.08%) 0.591 1982 (37.30%) 436 (44.81%) <0.001
Rheumatological
disease 478 (12.59%) 554 (22.26%) <0.001 998 (16.54%) 34 (13.49%) 0.201 769 (14.47%) 263 (27.03%) <0.001
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suburban areas were associated with greater mortality and with less hospital or ICU
hospitalisation. Distance from the hospital was also associated with hospital admission
such that the closer the patients’ residence was to the hospital, the greater the likelihood
that they would be admitted.
Table 3. Multivariate Cox models.
Variables
Hospital Admission ICU Admission Death
HR p 95% CI HR p 95% CI HR p 95% CI
Age 1.03 <0.001 1.02 1.03 1.08 <0.001 1.07 1.09
Sex
Male Ref Ref Ref
Female 0.59 <0.001 0.54 0.64 0.28 <0.001 0.21 0.38 0.54 <0.001 0.47 0.62
Area
Rural Ref Ref Ref
Suburban 0.77 0.002 0.65 0.91 0.50 0.011 0.29 0.85 1.31 0.022 1.04 1.66
Urban 1.14 0.054 1.00 1.30 1.02 0.930 0.71 1.46 1.23 0.047 1.00 1.51
Municipality—hospital distance 0.99 0.001 0.98 0.99
Comorbidities
Previous cardiovascular disease 1.14 0.006 1.04 1.26 1.18 0.018 1.03 1.35
Hypertension 1.12 0.034 1.01 1.24 1.43 0.010 1.09 1.89
Dyslipidaemia 1.35 <0.001 1.23 1.47 2.18 0.000 1.66 2.86
Previous respiratory disease 1.14 0.040 1.01 1.29
Chronic neurological disorder 1.14 0.021 1.02 1.27
Ulcerative disease/immunosuppression/previous
transplant 1.40 0.001 1.15 1.71
Chronic haematological disease (including leukaemia,
lymphoma, myeloma) 1.08 0.098 0.99 1.18 1.33 0.038 1.02 1.74 1.20 0.007 1.05 1.37
Neoplasia 1.12 0.049 1.00 1.27
Obesity 1.29 <0.001 1.14 1.46 2.04 <0.001 1.49 2.78
Diabetes 1.15 0.017 1.02 1.28 1.20 0.018 1.03 1.39
Dementia 0.86 0.024 0.75 0.98 0.10 <0.001 0.03 0.31 1.38 <0.001 1.20 1.59
Dermatological disease 1.08 0.085 0.99 1.18
Ref is the category used as a reference in the analysis.
In terms of the prognostic model of hospital admission, most of the comorbidities
studied were related to a poorer prognosis except for dementia (HR 0.86; 95% CI 0.75–0.98),
which acts as a protective factor for admissions but is still related to higher mortality.
In the ICU admission model, there were comorbidities such as CVD, neurological
disease and previous respiratory disease that disappeared from the final model. Only
hypertension (HR 1.43; 95% CI 1.09–1.89), dyslipidaemia (HR 2.18; 95% CI 1.66–2.86),
chronic haematological disease (HR 1.33; 95% CI 1.02–1.74) and obesity (HR 2.04; 95% CI
1.49–2.78) were associated with a poorer prognosis in terms of ICU admission.
Lastly, the comorbidities associated with mortality were CVD (HR 1.18; 95% CI
1.03–1.35), previous haematological disease (HR 1.20; 95% CI 1.05–1.37), diabetes (HR 1.20;
95% CI 1.03–1.39) and dementia (HR 1.38; 95% CI 1.20–1.59) (Table 3).
4. Discussion
The results of this study show how factors such as type of municipality and distance
to hospital can act as social health determinants and establish the outcomes of patients
with COVID-19. This study concurs with relevant studies in the literature on the prog-
nosis of patients with COVID-19 while showing that geographical factors are relevant to
the prognosis.
One of our relevant results, is that suburban areas were associated with increased
mortality and with lower hospital and ICU admission. The reduced accessibility of subur-
ban areas to hospitals compared with urban zones could be a causal factor in this higher
mortality; nevertheless, this is not the case in more rural areas, which have shown the
same associations as urban areas, despite the fact that, in Spain, individuals older than
65 years accounted for 28.5% of the population of rural communities [8]. It is probably
that small towns, which are typically further away from urban cities, are inhabited by an
older population with greater social isolation and less need to travel for work reasons, so
it is highly likely that the older population has been particularly cautious in the face of
the pandemic.
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Mixed results can be found for the type of municipality. A study conducted in India
showed that 1 in 4 COVID-19-related deaths occurred in rural and suburban districts [12];
however, the incidence and mortality rates in small and nonmetropolitan cities has been
comparable to those of large cities in the US [13]. In our study, 11.64% of the sample lived in
rural areas with similar hospitalisation rates than urban areas. In a recent systematic review,
the household and area-level social determinants of multimorbidity were analysed [23];
findings from the rural areas were inconsistent and insufficiently studied. In the same
review, distance from the hospital was associated with hospitalisation, such that the closer
the patient lived to the hospital (urban areas), the greater the likelihood that they would
be hospitalised [23]. In an analysis of avoidable hospitalisations in chronic diseases, the
patients’ place of residence explained only 33% of the variation in hospital admission [24].
Geographic differences in COVID-19 case, deaths and cumulative incidences likely
reflect a combination of epidemiologic and population-level factors, including the timing of
the start of the pandemic; population density; age distribution and prevalence of underlying
medical conditions; timing and extent of community mitigation measures; diagnostic
testing capacity; and public health practices [25].
Other variables in our study, age and sex, were significant factors in explaining the
prognosis of the patients diagnosed in PHC, which agrees with most previous studies that
have stated that male and older patients (≥ 50 years) are at higher risk of greater severity
and death [26–28]. Older adults had greater initial comorbidities, more severe symptoms
and are more likely to experience multiorgan involvement [27], whereas the sex disparity
in the outcomes of patients with COVID-19 could be explained by the fact that men are
more likely than women to experience severe forms of infection, and have higher mortality
rates and a higher prevalence of the main risk factors of COVID-19 [28]. Other explanations
include the mechanisms of viral infection, the immune response, and the development of
hyperinflammation and systemic complications, particularly thromboembolism. Women
therefore have a more favourable disease course than men, regardless of age range, al-
though the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
appears to be similar for both sexes [29]. Our results reinforce these findings, showing
a major difference in ICU admissions by sex, probably due to the lower severity of the
disease in women, making ICU admission unnecessary. Women’s greater longevity also
means that their deaths occur more frequently in non-hospital settings.
The presence of CVD, diabetes, dementia, hypertension, dyslipidaemia and obesity
were relevant to the outcomes of our 6286 patients with COVID-19. Other studies have
shown the influence of morbidities in COVID-19. A meta-analysis with 55 studies and
10,014 patients [24] showed that the presence of at least 1 comorbidity such as hyperten-
sion, diabetes, CVD, respiratory disease, CKD, etc., significantly increased the severity of
infection. Other studies and meta-analyses have obtained similar results [17,30–33].
Hypertension is associated with a nearly 2.5-fold increased risk of severe COVID-19
(OR 2.49; 95% CI 1.98–3.12; I2 = 24%) and a similarly significant higher mortality risk
(OR 2.42; 95% CI 1.51–3.90; I2 = 0%) [30]. CVD are also associated with an increased risk
of poor outcomes in patients with COVID-19 [18,32]. Diabetes in patients with COVID-19
is associated with a 2-fold increase in mortality and COVID-19 severity compared with
patients without diabetes [30], however, this negative impact might not be related to
hyperglycaemia per se but rather to the comorbidities associated, in the context of metabolic
syndrome, as well as CVD and CKD, which are common and severe complications of
chronic hyperglycaemia [17].
In our study, severity of COVID-19 appears to increase with increasing body mass
index (BMI). A study analysing 45,650 participants from 30 studies with obesity revealed
increased ORs of severe COVID-19 associated with higher BMI [34], may be associated to
a vitamin D deficiency, hinders immunity and causes mechanical lung compression [35].
Other potential pathophysiological mechanisms are the chronic proinflammatory state, the
excessive oxidative stress response and the impaired immunity that is commonly reported
in obesity [36]. Furthermore, pre-existing comorbidities increase these complications [35].
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Although the patients with dementia in our study had a higher mortality rate, the
disease acted as a protective factor for hospital admission, which could be because health
systems might be more reluctant to hospitalise patients with dementia and COVID-19,
especially in cases of saturated health systems. Patients with pre-existing neurological dis-
orders, can develop exacerbation of neurological symptoms and severe COVID-19 [37,38].
A high percentage of elderly patients with dementia admitted to ICU or isolated medical
departments experience neurological and neuropsychiatric symptoms and worsening of
their condition [38].
The main study strengths include the complex model, including geographic variables
related to the comorbidities and prognosis of patients with COVID-19. Our findings can
be extrapolated to other countries having similar population pyramids and geographic
dispersion. However, this study also has certain limitations, since variables such as income,
access to health care, and access to transportation were not collected or analyzed due to the
universal nature of the NHS. These variables may be relevant in countries that do not have
a universal NHS.
The current pandemic, like other previous pandemics, is occurring in the context of
social and health inequalities that need to be resolved [39,40]. This study has sought to
contribute knowledge to the current pandemic by analysing the comorbidities associated
with a large sample of patients with COVID-19, relating them to health determinants such
as age, sex, geographical accessibility to health services and place of residence.
In future studies, data should be compared with those of other countries, especially to
provide greater knowledge on the behaviour of health systems and methods for adjusting
the use of these systems to this new disease, reducing as much as possible the clinical and
epidemiologic variability and exploring the place of residence as a social determinant.
5. Conclusions
Factors such as type of municipality and distance to hospital act as social health
determinants. This fact must be taken account in order to establish specific prevention
measures and treatment protocols.
Author Contributions: Conceptualization: R.M.-B., B.O.-B.; data curation: F.M.-L.-d.-l.-M., M.C.-C.,
I.A.-P.; formal analysis: E.A.-E., B.O.-B., R.M.-B.; writing—original draft: R.M.-B., B.O.-B., E.A.-E,
K.L.R.-C.; writing—review & editing: All authors. All authors have read and agreed to the published
version of the manuscript.
Funding: This study has been funded by Instituto de Salud Carlos III through the projects COV20/00634
and COV20/00519 (Co-funded by European Regional Development Fund/European Social Fund “A
way to make Europe”/”Investing in your future”). We thank the redIAPP “Red de Investigación en
Actividades Preventivas y Promoción de la Salud” Primary Care Prevention and Health Promotion
Network (RD16/0007/0005 & RD16/0007/0001) for support in the development of this study.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki. Protocol was approved (13/05/2020) by the Clinical Research Ethics
Committee of Institute of Research of Aragón, IIS-Aragón (protocol code PI20/262).
Informed Consent Statement: Patient consent was waived because the data were obtained from the
big data of Public Health Service and patients were not identifiable.
Data Availability Statement: The data that support the findings of this study are available from the
corresponding author, upon reasonable request.
Acknowledgments: We wish to thank the Primary Care Prevention and Health Promotion Network
(RedIAPP-Health Institute Carlos III, Spain); Research Group B21_R17 of the Department of Research,
Innovation and University of the Government of Aragon (Spain); Feder Funds “A way to make
Europe”, for their support in the development of the study.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Environ. Res. Public Health 2021, 18, 3842 10 of 11
References
1. World Health Organization. Weekly Epidemiological Update. WHO. 2021. Available online: https://www.who.int/publications/
m/item/weekly-epidemiological-update---5-january-2021 (accessed on 7 January 2021).
2. Spanish Ministry of Health. Update No 284. Coronavirus Disease (COVID-19); Spanish Ministry of Health: Madrid, Spain,
2021. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/
Actualizacion_284_COVID-19.pdf (accessed on 5 January 2021).
3. Spanish Ministry of Health. Management of COVID-19 in Primary Health Care and Home Care; Spanish Ministry of Health: Madrid,
Spain, 2020. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/home.htm
(accessed on 7 January 2021).
4. Orús, A. Number of Coronavirus Medical Tests Performed Per Million Inhabitants in the Most Affected Countries in the
World. 2020. Available online: https://es.statista.com/estadisticas/1107740/covid-19-tasa-de-pruebas-realizadas-en-paises-
seleccionados-del-mundo/ (accessed on 8 January 2021).
5. OECD. Beyond Containment: Health Systems Responses to COVID 19 in the OECD; OECD: Paris, France, 2020. Available online:
https://read.oecd-ilibrary.org/view/?ref=119_119689-ud5comtf84&title=Beyond_Containment:Health_systems_responses_to_
COVID-19_in_the_OECD (accessed on 21 December 2020).
6. WHO Europe. European Observatory of Health Systems and Policies COVID-19 Health System Response Monitor Spain; WHO Europe:
Geneva, Switzerland, 2020. Available online: https://www.covid19healthsystem.org/countries/spain/livinghit.aspx?Section=3.
1Planningservices&Type=Section (accessed on 7 January 2021).
7. Government of Spain. Covid-19 in Spanish Rural Areas. Risk Factors and Opportunities to Improve the Quality of Life of the Elderly;
Government of Spain: Madrid, Spain, 2020. Available online: http://envejecimiento.csic.es/documentos/documentos/enred-
indicadoresbasicos2020.pdf (accessed on 21 December 2020).
8. Pérez Díaz, J.; Abellán García, A.; Aceituno Nieto, P.; Ramiro Fariñas, D. Un perfil de las personas mayores en España, 2020. In
Indicadores Estadísticos Básicos; CSHH-CSIC: Madrid, Spain, 2020. Available online: http://envejecimiento.csic.es/documentos/
documentos/enred-indicadoresbasicos2020.pdf (accessed on 16 October 2020).
9. Fóti, K. Eurofound. Is rural Europe being left behind? European Quality of Life Survey 2016; Publications Office of the European Union:
Luxembourg, 2019. Available online: https://www.eurofound.europa.eu/publications/policy-brief/2019/is-rural-europe-being-
left-behind (accessed on 15 November 2020).
10. Ministerio de Sanidad y Política Social. National Health System Spain; Ministerio de Sanidad y Política Social: Madrid, Spain, 2010.
11. Corominas, C. Spain Sets a New Minimum of Primary Health Centers and Falls to 2012 Levels; Redacción Médica: Madrid, Spain, 2017.
Available online: https://www.redaccionmedica.com/secciones/sanidad-hoy/espana-marca-un-nuevo-minimo-de-centros-
de-salud-13-163-al-nivel-de-2012-7402 (accessed on 16 November 2020).
12. Gera, I. Covid-19: A Fourth of all Deaths Are in Rural, Semi-Urban India; Financial Express: Delhi, India, 2020. Available online:
https://www.financialexpress.com/lifestyle/health/covid-19-a-fourth-of-all-deaths-are-in-rural-semi-urban-india/2092903/
(accessed on 29 September 2020).
13. Zhang, C.H.; Schwartz, G.G. Spatial Disparities in Coronavirus Incidence and Mortality in the United States: An Ecological
Analysis as of May 2020. J. Rural Heath 2020, 36, 433–445. [CrossRef]
14. Statistics National Institute. Statistical Information for the Analysis of the Impact of the COVID-19 Crisis. 2020. Available online:
https://www.ine.es/covid/covid_inicio.htm (accessed on 7 January 2021).
15. Regional Quantitative Analysis Research Group (AQR–UB). Differences between Urban and Rural Municipalities in the Spread of
COVID-19 in the Catalan Territory; AQR–University of Barcelona: Barcelona, Spain, 2020. Available online: http://www.ub.edu/
(accessed on 21 December 2020).
16. Jain, V.; Yuan, J.M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: A systematic
review and meta-analysis. Int. J. Public Health 2020, 65, 533–546. [CrossRef]
17. Pugliese, G.; Vitale, M.; Resi, V.; Orsi, E. Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? Acta Diabetol.
2020, 57, 1275–1285. [CrossRef] [PubMed]
18. Tian, W.; Jiang, W.; Yao, J.; Nicholson, C.J.; Li, R.H.; Sigurslid, H.H.; Wooster, L.; Rotter, J.I.; Guo, X.; Malhotra, R. Predictors
of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 2020, 92, 1875–1883.
[CrossRef] [PubMed]
19. World Health Orgaization. CIE-11. Available online: https://icd.who.int/es (accessed on 16 January 2021).
20. Kolassa, J.E. An Introduction to Nonparametric Statistics; CRC Press, Taylor and Francis Group: Boca Raton, FL, USA, 2020;
ISBN 9780367194840.
21. Kleinbaum, D.G.; Klein, M. Survival Analysis: A Self-Learning Text, 3rd ed.; Springer: New York, NY, USA, 2012.
22. Villers Gómez, S.; Vásquez Guerra, C.F.; Ramírez Teodoro, L.A. Modelos de Supervivencia. [Survival Models]. Available online: https:
//carlosfernandovg.github.io/supervivencia_y_series_FC2021-1/an%C3%A1lisis-de-supervivencia.html (accessed on 31 March 2021).
23. Ingram, E.; Ledden, S.; Beardon, S.; Gomes, M.; Hogarth, S.; McDonald, H.; Osborn, D.P.; Sheringham, J. Household and area-level
social determinants of multimorbidity: A systematic review. J. Epidemiol. Community Health 2020. [CrossRef]
24. Angulo-Pueyo, E.; Martínez-Lizaga, N.; Bernal-Delgado, E. Wide systematic variations in potentially avoidable hospitalisations
of chronically ill patients: Ecological study of basic health areas and healthcare areas. Rev. Clin. Esp. 2020. [CrossRef]
Int. J. Environ. Res. Public Health 2021, 18, 3842 11 of 11
25. CDC COVID-19 Response Team. Geographic Differences in COVID-19 Cases, Deaths, and Incidence—United States.
MMWR Morb. Mortal. Wkly. Rep. 2020, 17, 465–471. [CrossRef]
26. Barek, M.A.; Aziz, M.A.; Islam, M.S. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases:
A meta-analysis with 55 studies and 10014 cases. Heliyon 2020, 6, e05684. [CrossRef]
27. Chen, T.; Dai, Z.; Mo, P.; Li, X.; Ma, Z.; Song, S.; Chen, X.; Luo, M.; Liang, K.; Gao, S.; et al. Clinical Characteristics and Outcomes of
Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study. J. Gerontol.
Ser. A Biol. Sci. Med. Sci. 2020, 75, 1788–1795. [CrossRef] [PubMed]
28. Khalatbari-Soltani, S.; Cumming, R.C.; Delpierre, C.; Kelly-Irving, M. Importance of collecting data on socioeconomic determi-
nants from the early stage of the COVID-19 outbreak onwards. J. Epidemiol. Community Health 2020, 74, 620–623. [CrossRef]
29. Pivonello, R.; Auriemma, R.S.; Pivonello, C.; Isidori, A.M.; Corona, G.; Colao, A.; Millar, R.P. Sex disparities in Covid-19 severity
and outcomes: Are men weaker or women stronger? Neuroendocrinology 2020. [CrossRef] [PubMed]
30. Kumar, A.; Arora, A.; Sharma, P.; Anikhindi, S.A.; Bansal, N.; Singla, V.; Khare, S.; Srivastava, A. Is diabetes mellitus associated
with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 535–545. [CrossRef]
[PubMed]
31. Lippi, G.; Wong, J.; Henry, B.M. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Pol. Arch.
Intern. Med. 2020, 130, 304–309. [CrossRef]
32. Pranata, R.; Huang, I.; Lim, M.A.; Wahjoepramono, E.J.; July, J. Impact of cerebrovascular and cardiovascular diseases on mortality
and severity of COVID-19–systematic review, meta-analysis, and meta-regression. J. Stroke Cerebrovasc. Dis. 2020, 29. [CrossRef]
33. Pranata, R.; Lim, M.A.; Huang, I.; Raharjo, S.B.; Lukito, A.A. Hypertension is associated with increased mortality and severity
of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. JRAAS J. Renin Angiotensin
Aldosterone Syst. 2020, 21. [CrossRef]
34. Huang, Y.; Lu, Y.; Huang, Y.-M.; Wang, M.; Ling, W.; Sui, Y.; Zhao, H.-L. Obesity in patients with COVID-19: A systematic review
and meta-analysis. Metabolism 2020, 113, 154378. [CrossRef]
35. Cuschieri, S.; Grech, S. Obesity population at risk of COVID-19 complications. Glob. Health Epidemiol. Genom. 2020, 5. [CrossRef]
36. Caci, G.; Albini, A.; Malerba, M.; Noonan, D.M.; Pochetti, P.; Polosa, R. COVID-19 and Obesity: Dangerous Liaisons. J. Clin. Med.
2020, 9, 2511. [CrossRef]
37. Kubota, T.; Kuroda, N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological
disorders and COVID-19: A systematic review. Clin. Neurol. Neurosurg. 2020. [CrossRef]
38. Ryoo, N.; Pyun, J.-M.; Baek, M.J.; Suh, J.; Kang, M.J.; Wang, M.J.; Youn, Y.C.; Yang, D.W.; Kim, S.Y.; Park, Y.H.; et al. Coping with
Dementia in the Middle of the COVID-19 Pandemic. Int. J. Agric. Biol. 2020, 35, 1–21. [CrossRef]
39. OECD Health Policy Studies. Geographic Variations in Health Care. In What Do We Know and What Can Be Done to Improve Health
System Performance? OECD: Paris, France, 2014.
40. Bambra, C.; Riordan, R.; Ford, J.; Matthews, F. The COVID-19 pandemic and health inequalities. J. Epidemiol. Community Health
2020, 74, 964–968. [CrossRef] [PubMed]
